Neurocrine Biosciences | NBIX - Trade Debtors

Stock Price
142.72
Daily Change
-1.38 -0.96%
Monthly
11.13%
Yearly
18.77%
Q3 Forecast
142.90

Neurocrine Biosciences reported $595.7M in Trade Debtors for its fiscal quarter ending in June of 2025.




Trade Debtors Change Date
AbbVie USD 12.48B 1.56B Mar/2025
Acadia Pharmaceuticals USD 119.69M 5.97M Jun/2025
Agios Pharmaceuticals USD 4.99M 1.64M Jun/2025
ALKERMES USD 356.33M 34.58M Jun/2025
Alnylam Pharmaceuticals USD 567.11M 149.08M Jun/2025
Amgen USD 8.7B 569M Jun/2025
Biogen USD 2.08B 87.5M Jun/2025
BioMarin Pharmaceutical USD 855.85M 116.68M Jun/2025
Cytokinetics USD 8.41M 6.4M Jun/2025
Dynavax Technologies USD 73.34M 16.79M Jun/2025
Exelixis USD 292.35M 10.72M Jul/2025
Gilead Sciences USD 4.78B 393M Jun/2025
Halozyme Therapeutics USD 316.34M 11.72M Jun/2025
Incyte USD 842.89M 19.76M Jun/2025
Ionis Pharmaceuticals USD 52.58M 12.87M Jun/2025
Neurocrine Biosciences USD 595.7M 79.7M Jun/2025
Pfizer USD 16.09B 1.35B Jun/2025
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 5.61B 49M Jun/2025
Repligen USD 147.41M 13.3M Mar/2025
Sarepta Therapeutics USD 609.6M 114.93M Jun/2025
Teva Pharmaceutical Industries USD 3.56B 180M Jun/2025
Ultragenyx Pharmaceutical USD 124.46M 25.62M Jun/2025
Vertex Pharmaceuticals USD 1.89B 88.4M Jun/2025